Hakop Gevorkyan

Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033

Jonathan Q. Tran, Jitesh Rana, Frederik Barkhof et al. · Neurology Neuroimmunology & Neuroinflammation · 2014 · 121 citations · Full text

The effect of LCZ696 (sacubitril/valsartan) on amyloid‐β concentrations in cerebrospinal fluid in healthy subjects

Thomas Langenickel, Chiaki Tsubouchi, Surya Ayalasomayajula et al. · British Journal of Clinical Pharmacology · 2015 · 109 citations · Full text

O1–06–05: The novel BACE inhibitor MK‐8931 dramatically lowers CSF beta‐amyloid in patients with mild‐to‐moderate Alzheimer's disease

Mark S. Forman, Huub‐Jan Kleijn, Marissa F. Dockendorf et al. · Alzheimer s & Dementia · 2013 · 40 citations · Full text

Placebo Administration, Dose-response Profiles, Neurochemical Biomarkers +21

A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor

Max Tsai, Lambros Chrones, Jinhui Xie et al. · Psychopharmacology · 2016 · 20 citations · Full text

Safety, pharmacokinetics and quantitative EEG modulation of TAK‐071, a novel muscarinic M1 receptor positive allosteric modulator, in healthy subjects

Wei Yin, Fahimeh Mamashli, Derek L. Buhl et al. · British Journal of Clinical Pharmacology · 2021 · 20 citations · Full text